Day: June 1, 2023

Stag Handling Corner Stag Handling Corner at Rally Ready Track During Stag Demo Day EventStag Catching Air NASDAQ: VLCN Gives Key Contacts an Inside Look at Flagship Product, the Stag, at Demo Day EventAriel Shot of Volcon Stag Demo Day Ariel Shot of Volcon Stag Demo Day Setup at Rally Ready TrackRace Stag In Front of Lost Pines Volcon Race Stag In Front of Lost PinesAUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company invited key media, dealers and international distributors to test drive prototype models of the Company’s flagship product, the Stag, during a VIP Demo Day event held before Memorial Day Weekend. The Company hosted the event at the Hyatt Regency Lost Pines Resort in Cedar Creek, Texas, where...

Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improve the safety of ASC-based cell therapy FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT). The paper, “Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic...

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City.When: Thursday, June 8th at 4:30 pm Eastern timeLive Webcast: https://wsw.com/webcast/jeff281/sava/1846130Archived Replay: https://www.CassavaSciences.com/company-presentations   About SimufilamSimufilam is Cassava Sciences’ lead product candidate. Simufilam is a proprietary small molecule (oral) drug designed to treat and slow the progression of Alzheimer’s disease. This drug candidate is currently in Phase 3 clinical studies in patients with mild-to-moderate Alzheimer’s disease dementia. Simufilam binds tightly to an altered conformation...

CLEVELAND, OHIO, June 01, 2023 (GLOBE NEWSWIRE) — MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite” or “Company”), a public company focused on improving the health and wellness of people and the planet, today announced the continued expansion of its senior leadership team with the hiring of Dr. Erick Carlson as its new Riparian Ecologist, Patricia Missal as its new Corporate Controller, and Reese Fields as its new Business Development Manager. Dr. Erick Carlson, Riparian Ecologist The Company has engaged Dr. Carlson to serve as a consultant to the Company’s environmental services businesses, with a particular focus on its Terra Preta business unit. He will assist the Company’s senior management team in developing innovative solutions to reclaim lands and restore waterways in Appalachia. Dr. Carlson is a riparian ecologist...

Long Island Consumers Set to Enjoy Greater Access to the Company’s Fresh, Sustainably Grown Produce Broadened Presence Presents Opportunity to Boost Third-Quarter Revenue BELVIDERE, NJ, June 01, 2023 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today announced an expansion of its distribution partnership with King Kullen and IGA across all of their retail locations on Long Island, New York. Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, “We are pleased to broaden our distribution at both King Kullen and IGA retail locations across Long Island, New York, in time for the 2023 summer season. In response to growing consumer demand for...

MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being held June 7-9, 2023 at the Marriot Marquis in New York. Senior management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is...

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC) has granted approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. BRIUMVI was granted approval by the U.S. Food and Drug Administration on December 28, 2022, for the treatment of RMS in adults. BRIUMVI is the first and only anti-CD20 monoclonal antibody approved in the U.S. and now the European Union (EU) for adult patients with RMS that can be administered in a one-hour infusion following the starting dose. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We are very pleased that the European Commission has approved BRIUMVI for...

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company’s new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commercial stage med-tech company focused on remote patient monitoring. Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led...

BACK TO THE FUTURE WITH CLOSED-END FUNDSA video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d5522b78-cf88-4830-b150-38763f653351. RYE, N.Y., June 01, 2023 (GLOBE NEWSWIRE) — Gabelli Funds is pleased to present an entertaining and educational video tracing the incredible growth of The Closed-End Fund industry over the last four decades. Though they are often overlooked, Closed-End Funds are one of the oldest forms of pooled investment vehicles, even predating more widely recognizable mutual funds and ETFs. The video highlights many closed-end funds that survived the Great Depression and continue to trade today on the New York Stock Exchange, offering investors access to extraordinary long-term investment results. The video features how closed end funds have...